Clinical Trial Documents into Chinese: Define the File Set and Review

Define the trial-document set before translating

Clinical-trial documents translated into Chinese need a file inventory and a named use for the translation. Identify the source language, document owner, study reference and source version for every item. Confirm which Chinese readers will use the set and whether the output is for internal review or another stated purpose.

List the actual document titles rather than assuming that a broad request for clinical files includes every study document. Mark related appendices and any source items still awaiting confirmation. A register makes the quotation and later review scope visible without reproducing sensitive study content in the initial inquiry.

A case report form (CRF) and a clinical study report (CSR) are different document types. A CRF collects protocol-required information for individual participants; a CSR brings together the clinical and statistical account of a study. For quotation, distinguish a blank form or field-label export from a completed record, and a complete report from selected sections and appendices. The FDA E6(R3) glossary is a reference for these document names, not a list of Chinese submission requirements.

From reading to a project

Connect the source team with Chinese review

Illustrative review sheet01

Clinical-file scope register · self-created

Blank CRF / form text

DEMO-CRF-01 · English rev. B · field labels and instructions only; no participant entries

CSR / report set

DEMO-CSR-01 · English rev. C · report plus listed appendices; confirm the included files

Stable references

Keep field IDs, table numbers, units and appendix references matched to the source

Chinese review handover

病例报告表 DEMO-CRF-01（B版）：字段标签及说明；临床研究报告 DEMO-CSR-01（C版）：正文与所列附录

Question owner

DEMO-Q1 · source location, question owner and agreed answer before updating the Chinese file

Review status: questions to confirm

1. 1

   Source team → translation

   Name the current source-version owner and the person who answers scientific questions.

2. 2

   Chinese review → decisions

   Return comments with the document revision and passage reference; distinguish wording comments from source changes.

3. 3

   Decisions → return set

   Identify who confirms the agreed changes and which Chinese files must be updated.

Related published experience

Shanghai Green Valley Pharmaceuticals→

English → Chinese

Drug-development agreements and clinical-trial documentation.

Green Valley records English-to-Chinese clinical-trial documentation and drug-development agreements. Its public case does not name CRF or CSR files. The register above is a self-created preparation example.

For your quotation

List the source-version owner, scientific question owner and Chinese review owner with the actual file inventory. Agree how comments and source replacements are returned; discuss confidentiality before sending sensitive files.

Prepare a Chinese clinical-document brief →Compare the relevant industry documents →

Plan English-to-Chinese files →Use the existing document registers →Individual patient records instead? →

Keep document identity and terminology decisions together

Use stable document references to connect the source, Chinese working file, reviewer comments and approved return file. Preserve the distinction between a document revision and a change to the study itself. If a source is replaced during translation, identify the affected sections instead of silently overwriting the review baseline. For a protocol amendment, supply the amendment reference and a brief change summary, plus any existing Chinese version with its matching source revision. This lets reviewers distinguish reusable wording from passages that need a new comparison.

Provide approved study-specific terms, product names and existing Chinese references that may be reused. Flag an unclear abbreviation or inconsistent source statement with its location and request a decision from the document owner. Translation should preserve the source meaning rather than supply a missing clinical or scientific conclusion.

For a CRF form or field-label export, identify the form version, field IDs, instructions and any text that must remain unchanged. For a CSR, identify the report version, included tables and appendices, and which files the Chinese reviewers will receive. Keep numbers, units, codes and cross-references tied to their source locations; ask the source owner about inconsistencies rather than resolving them by guesswork.

Agree the handover between the source team and Chinese reviewers

Before translation, name the source-version owner, the person who can answer scientific questions and the Chinese review owner. These roles may sit with different organizations. State who can approve wording and who confirms the final return set; a translator should not be left to choose between conflicting reviewer instructions.

When comments or a replacement source arrive, identify the document revision and affected passages. Keep source changes separate from Chinese wording comments, record the agreed answer and identify which files need updating. A marked-up Chinese working file and a source-change list are different inputs; agree which one controls the next revision.

Select the required return files, such as a bilingual comparison, tracked changes, terminology decisions or open questions. Agree these review and handover requirements in the quotation. Discuss confidentiality and the permitted transfer method before sharing sensitive files; a redacted representative sample can be enough for initial scoping. The responsible team supplies any formal submission requirements.

For a protocol amendment, identify the affected visits, eligibility criteria and endpoints, and compare each revised reference against the current schedule of assessments. Set aside participant-facing materials for a separate audience and terminology review.

Compare the Green Valley scope with the right file category

The Green Valley Pharmaceuticals case records English-to-Chinese drug-development agreements and clinical-trial documentation. That supports the broad document category and language direction. It does not identify a particular trial phase, protocol type, patient dataset or approval outcome. The public record does not identify CRF or CSR delivery; the file distinctions here are preparation guidance.

This guide concerns a study-related document set and its review responsibilities. For individual patient records, use the separate medical-record handover guide. For device technical files, see device-document preparation. For the meaning of a protocol amendment and a short version map, see the protocol-amendment reference. Continue through English-to-Chinese services with your actual file inventory.

For agreement files, use the separate drug-development agreement guide to prepare party names, defined terms and appendix references.